Cargando…
Treatment approach to type 2 diabetes: Past, present and future
Type 2 diabetes mellitus (DM) is a lifelong metabolic disease, characterized by hyperglycaemia which gradually leads to the development and progression of vascular complications. It is recognized as a global burden disease, with substantial consequences on human health (fatality) as well as on healt...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304295/ https://www.ncbi.nlm.nih.gov/pubmed/30588282 http://dx.doi.org/10.4239/wjd.v9.i12.209 |
_version_ | 1783382327255105536 |
---|---|
author | Blaslov, Kristina Naranđa, Fran Stjepan Kruljac, Ivan Renar, Ivana Pavlić |
author_facet | Blaslov, Kristina Naranđa, Fran Stjepan Kruljac, Ivan Renar, Ivana Pavlić |
author_sort | Blaslov, Kristina |
collection | PubMed |
description | Type 2 diabetes mellitus (DM) is a lifelong metabolic disease, characterized by hyperglycaemia which gradually leads to the development and progression of vascular complications. It is recognized as a global burden disease, with substantial consequences on human health (fatality) as well as on health-care system costs. This review focuses on the topic of historical discovery and understanding the complexity of the disease in the field of pathophysiology, as well as development of the pharmacotherapy beyond insulin. The complex interplay of insulin secretion and insulin resistance developed from previously known “ominous triumvirate” to “ominous octet” indicate the implication of multiple organs in glucose metabolism. The pharmacological approach has progressed from biguanides to a wide spectrum of medications that seem to provide a beneficial effect on the cardiovascular system. Despite this, we are still not achieving the target treatment goals. Thus, the future should bring novel antidiabetic drug classes capable of acting on several levels simultaneously. In conclusion, given the raising burden of type 2 DM, the best present strategy that could contribute the most to the reduction of morbidity and mortality should be focused on primary prevention. |
format | Online Article Text |
id | pubmed-6304295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-63042952018-12-26 Treatment approach to type 2 diabetes: Past, present and future Blaslov, Kristina Naranđa, Fran Stjepan Kruljac, Ivan Renar, Ivana Pavlić World J Diabetes Review Type 2 diabetes mellitus (DM) is a lifelong metabolic disease, characterized by hyperglycaemia which gradually leads to the development and progression of vascular complications. It is recognized as a global burden disease, with substantial consequences on human health (fatality) as well as on health-care system costs. This review focuses on the topic of historical discovery and understanding the complexity of the disease in the field of pathophysiology, as well as development of the pharmacotherapy beyond insulin. The complex interplay of insulin secretion and insulin resistance developed from previously known “ominous triumvirate” to “ominous octet” indicate the implication of multiple organs in glucose metabolism. The pharmacological approach has progressed from biguanides to a wide spectrum of medications that seem to provide a beneficial effect on the cardiovascular system. Despite this, we are still not achieving the target treatment goals. Thus, the future should bring novel antidiabetic drug classes capable of acting on several levels simultaneously. In conclusion, given the raising burden of type 2 DM, the best present strategy that could contribute the most to the reduction of morbidity and mortality should be focused on primary prevention. Baishideng Publishing Group Inc 2018-12-15 2018-12-15 /pmc/articles/PMC6304295/ /pubmed/30588282 http://dx.doi.org/10.4239/wjd.v9.i12.209 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Blaslov, Kristina Naranđa, Fran Stjepan Kruljac, Ivan Renar, Ivana Pavlić Treatment approach to type 2 diabetes: Past, present and future |
title | Treatment approach to type 2 diabetes: Past, present and future |
title_full | Treatment approach to type 2 diabetes: Past, present and future |
title_fullStr | Treatment approach to type 2 diabetes: Past, present and future |
title_full_unstemmed | Treatment approach to type 2 diabetes: Past, present and future |
title_short | Treatment approach to type 2 diabetes: Past, present and future |
title_sort | treatment approach to type 2 diabetes: past, present and future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304295/ https://www.ncbi.nlm.nih.gov/pubmed/30588282 http://dx.doi.org/10.4239/wjd.v9.i12.209 |
work_keys_str_mv | AT blaslovkristina treatmentapproachtotype2diabetespastpresentandfuture AT naranđafranstjepan treatmentapproachtotype2diabetespastpresentandfuture AT kruljacivan treatmentapproachtotype2diabetespastpresentandfuture AT renarivanapavlic treatmentapproachtotype2diabetespastpresentandfuture |